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Introduction: The Mediterranean Diet (MD) is useful in the prevention of overweight, 
obesity and metabolic disease. High Quality-Extra Virgin Olive Oil (HQ-EVOO), an essential 
component of this diet, exerts protective effects against chronic diseases. Gut Microbiota 
(GM), recognized as a key factor in driving metabolic activities, is involved in the regulation 
of host immunity. Lactic Acid Bacteria (LAB) and their probio-active cellular substances 
produce beneficial effects in the gastrointestinal tract.
Materials and Methods: Eighteen overweight/obese subjects (cases, BMI ≥25 kg/m2) and 
18 normal weight controls (BMI 18.5–24.9 kg/m2) were fed with MD enriched with 40 
g/die HQ-EVOO for three months. Feces and blood samples were collected at time 0 
(T0) and after three months (T1) for LAB composition, oxidative stress, metabolic and 
inflammation parameter determinations.
Results: Myeloperoxidase and 8-hydroxy-2-deoxyguanosine, markers of inflammation 
and oxidative stress, were significantly decreased after MD rich in HQ-EVOO both in 
controls and in cases. Proinflammatory cytokines levels were significantly decreased in 
cases in comparison to controls, while IL-10 and adiponectin were significantly increased 
in cases. LAB’s rpoB copies/ng of DNA increased 55.6 folds in cases compared to their 
baseline after MD rich in HQ-EVOO. MD rich in HQ-EVOO increased adiponectin and 
IL-10 concentration in overweight/obese subjects and decreased oxidative stress and 
inflammation parameters and at the same time, increased LAB number in GM.
Discussion: Our results indicate that MD rich in HQ-EVOO induces an increase of LAB 
in GM and could have a potential role in the prevention of inflammation.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03441802.
Keywords: mediterranean diet, high quality-extra virgin olive oil, cytokines, adiponectin, microbiota, lactic acid 
bacteria, prevention and rehabilitation
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INTRODUCTION
In Systems Medicine, human being is considered as a complex of 
cells functionally connected, organized and integrated together, 
with the aim of maintaining a dynamic stability through 
continuous adapting to the external environment. Overweight 
and obesity could unsettle this equilibrium predisposing to 
metabolic syndrome and development of chronic diseases 
(Poirier et al., 2006).
The pathogenesis for overweight, obesity and some metabolic 
diseases is multifactorial, involving a complex interaction of 
genetic, socio-economic, behavioral and environmental aspects. 
Recently, several studies shed light on a possible correlation 
between these pathological conditions and alterations in the Gut 
Microbiota (GM) composition. For instance, evidence indicates 
beneficial and/or harmful effects on some chronic diseases related 
with GM differential composition. Furthermore, modification of 
GM is associated with increased risk of metabolic and immune 
disorders in animals and humans (Boulangé et al., 2016). 
High fat and high sugar diets may alter intestinal microbiota 
independently from differences in host genotype, causing 
modifications responsible for some of the medical disorders 
observed in metabolic syndrome (Murphy et al., 2015).
In a recent systematic review and meta-analysis, GM was 
described as one of the most important risk factors affecting 
obesity (John et al., 2018), whereby distal GM of obese subjects 
is different in the relative composition and abundance of bacteria 
in comparison with non-obese subjects (Turnbaugh et al., 2006).
Native bacteria are mainly acquired at birth and during the 
first year of life, whereas transient bacteria, the most part of GM, 
are continuously ingested with food and drinks and their number 
and composition is modified by life style (Dueñas et al., 2015). 
Among these microorganisms, Lactic Acid Bacteria (LAB) include 
a large number of genera such as lactobacilli considered as safe 
for their hosts, and implicated in the pathogenesis of a number of 
clinical conditions as diverse as obesity, Cardio Vascular Disease 
(CVD), inflammatory bowel diseases (Kinross et al., 2011); 
moreover, complex molecular cross-talk between LAB and host 
has been demonstrated. LAB produce moonlighting proteins, 
promote bacterial adhesion to mucosa and stimulate immune 
cells in response to gut stimuli, and are considered antioxidant 
and nutraceutical vectors (Pessione, 2012).
Interest for LAB and their potential has recently increased 
since they were recognized as probiotic agents with an important 
role in the animal gut ecosystem, as demonstrated in different 
studies on germ free animals which showed their need of an 
additional nutritional intake to maintain their ideal weight 
(Kallus and Brandt, 2012). Previous publications demonstrate 
that diet consistently influences the intestinal ecosystem and 
functional capacity of GM of adults and children (Delzenne 
et al., 2011; Danneskiold-Samsøe et al., 2019).
The Mediterranean Diet (MD) is the gold standard for 
a healthy nutrition and it is associated with reduced risk of 
metabolic disease. Its beneficial effect has been attributed not 
only to macronutrients but also to micronutrients as well as 
prebiotics, probiotics and other components which can modulate 
GM. As one of the main constituent of MD, Extra Virgin Olive 
Oil has a major beneficial role attributed to oleic acid and to 
polyphenols, that exert antioxidant activity positively influencing 
several biomarkers of oxidative damage (Hidalgo et al., 2014; 
Trichopoulou et al., 2014; Gambino et al., 2017; Estruch et al., 
2018; Danneskiold-Samsøe et al., 2019)
These polyphenols are directly absorbed or metabolized in the 
intestine or transformed in active metabolites where they might 
exert a significant local action in relation to their interaction 
with the GM. They potentially modulate the oxidative status of 
intestinal barrier, inflammation and immune response of the 
host (Deiana et al., 2018).
There is growing evidence that inflammation and oxidative 
stress are closely related, creating a vicious circle that can aggravate 
metabolic disease. A low grade inflammation is associated to 
obesity and adipose tissue releases many active mediators, such 
as leptin and adiponectin, as well as classical pro-inflammatory 
cytokines (Feillet-Coudray et al., 2019).
Based on this evidence, the aim of this research was to study, if 
and how, some parameters of inflammation and oxidative stress 
and GM’s LAB number copies, change after 3 months of MD rich 
in High Quality-Extra Virgin Olive Oil (HQ-EVOO) in a cohort 
of overweight/obese subjects in comparison with normal weight 
controls. The HQ-EVOO is defined according to the Italian 
regulation of “high quality” extra virgin olive oil (Annex A) of 
the Ministry of Agriculture, Food, Forestry and Tourism.
MATERIAlS AND METHODS
Enrollment of Subjects
Subjects were recruited at Don Gnocchi Foundation, Florence, 
Italy. A written informed consent was obtained from each 
participant. The study was approved by the Ethics Committee of 
Don Gnocchi Foundation and performed following the Ethical 
standards of the Declaration of Helsinki, 1964 and its later 
amendments (Carlson et al., 2004). The number of ClinicalTrials.
gov Identifier is NCT03441802.
Inclusion criteria: BMI ≥18.5 kg/m2.
Exclusion criteria: Subjects suffering of eating disorders and 
in recent (1 month) or ongoing antibiotic therapy.
We enrolled 36 individuals, 17 males and 19 females, eligible 
in the study.
Subjects were divided in two arms according to their BMI: 
controls had normal weight (BMI between 18.5 and 24.9 kg/m2). 
They were 6 males and 12 females and at enrollment they were 
following MD, evaluated by a specific score (Sofi et al., 2014). 
Cases were overweight/obese subjects (BMI ≥25 kg/m2). Not all 
cases, only 11 males and 7 females, at enrollment, followed a MD 
according to the score criteria.
At enrollment, all the participants to the study received 
the same procedures and evaluations. At time 0 (T0) all the 
participants were submitted to anamnestic, anthropometric and 
dietetic assessments: height was measured on a wall-mounted 
stadiometer, weight was measured on a leveled platform scale and 
BMI was calculated as weight (kg)/height (m2). The adherence to 
the MD was evaluated by a specific score from 0 to 18 (0 minimal 
adherence; 18 greatest adherence) (Sofi et al., 2014). The diet was 
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analyzed using the WinFood database (Medimatica, Teramo, 
Italy) according to the table of food consumption of the Italian 
National Institute of Nutrition and to the Food Composition 
Database for Epidemiologic Study in Italy. The survey items 
reported the quantities and frequency of food consumption 
such as cereals, vegetables and fruit, beans, fish, poultry, dairy 
products, milk, fats and oils, eggs, meat, sweets, salt, alcohol and 
other beverages (Salvini et al., 1996).
After enrollment all subjects followed a typical MD (55–60% 
carbohydrates, mainly complex ones, 25–30% polyunsaturated 
and monounsaturated fats, 15–20% proteins) (Luisi et al., 
2015) and cases received a low-calorie MD (Kcal 1,552 ± 160). 
Both cases and controls utilized 40 g/die of HQ-EVOO for 3 
months as the only cooking and dressing fat. HQ-EVOO main 
constituents are reported in Table 1 and the analysis were 
performed by the Valoritalia Laboratories s.r.l., Tavarnelle Val di 
Pesa, Florence, Italy.
Anthropometric assessments, questionnaires, blood and fecal 
samples were obtained at T0 and repeated after 3 months of MD 
rich in HQ-EVOO (T1).
The enrolled individuals followed these drug therapies: one 
case, affected by type 2 diabetes, received metformin (250 mg × 
2/die); four participants had hypertension and were treated with 
ramipril (5 mg/die).
Biochemical Analysis
Ematochemical parameters: All blood samples were immediately 
placed on ice and centrifuged at 4°C, after which the plasma 
was removed. Plasma was stored at −80°C until analysis. Plasma 
glucose was estimated using a Beckton Dickinson blood sugar 
assay kit. Ten microliters of plasma was mixed with 90 µl of reagent 
consisting of glucose oxidase-peroxidase-O-dianisidine.  After 
10 min, the Optical density (OD) of the complex was measured 
at 620 nm in an autoanalyzer. Plasma insulin was measured using 
a human insulin ELISA kit (Novus Biologicals–Bio-Techne Ltd, 
Abingdon, UK); while plasma C-peptide concentrations were 
assayed by an ultrasensitive C-peptide ELISA kit (Mercordia 
AB8, Uppsala, Sweden). The assay was calibrated against 
International Reference Reagent for C-peptide (IRR-C-peptide, 
a WHO standard).
Determination of adiponectin levels: Adiponectin, an adipocyte-
specific protein, which plays a role in the development 
of insulin resistance, was measured in plasma using a 
commercially available ELISA kit (Adipo Bioscience, Santa 
Clara, CA, USA). The assay was carried out according to the 
manufacturer procedures. The developed color was measured 
spectrophotometrically using the micro plate reader at 450 
nm. Adiponectin concentrations, in μg/ml, were calculated 
from the standard curve prepared using recombinant human 
adiponectin standards.
Determination of 8-hydroxy-2-deoxy-guanosine (8-OHdG): 
levels of 8-OHdG, a marker of oxidative DNA damage, were 
measured on plasma (Lucarini et al., 2017). Briefly, frozen 
plasma samples were added with 1 ml of 10 mmol/l Tris–HCl 
buffer, pH 8, containing 10 mmol/l EDTA, 10 mmol/l NaCl, 
and 0.5% SDS, incubated for 1 h at 37°C with 20 μg/ml RNase 1 
(Sigma‐Aldrich, Saint Louis, MO, USA) and overnight at 37°C 
under argon in the presence of 100 μg/ml proteinase K (Sigma‐
Aldrich). The mixture was extracted with chloroform/isoamyl 
alcohol (10/2 v/v). DNA was precipitated from the aqueous phase 
with 0.2 volumes of 10 mmol/l ammonium acetate, solubilized 
in 200 μl acetate buffer, pH 5.3 and denatured at 90°C for 3 min. 
The extract was then supplemented with 10 IU of P1 nuclease 
(Sigma‐Aldrich) in 10 μl and incubated for 1 h at 37°C with 5 IU 
of alkaline phosphatase (Sigma‐Aldrich) in 0.4 mol/l phosphate 
buffer, pH 8.8. All of the procedures were performed in the dark 
under argon. The mixture was filtered by an Amicon Micropure‐
EZ filter (Merck‐Millipore, Milan, Italy) and 50 μl of each 
sample was used for 8‐OHdG determination using a ELISA kit 
(JalCA, Shizuoka, Japan), following the instructions provided by 
the manufacturer. The absorbance of the chromogenic product 
was measured at 450 nm and expressed as ng/mg of DNA. The 
results were calculated from a standard curve based of 8‐OHdG 
solution. The values are expressed as ng 8‐OHdG/ng total DNA.
Determination of malonyldialdehyde (MDA): the measurement 
of lipid peroxidation in plasma samples was based on the 
reaction of MDA, the end product of the process, with 
2-thiobarbituric acid (TBA) to form a chromophore absorbing 
at 532 nm. The reaction mixture (0.4 ml of sample; 0.2 ml 
of 2 mM chlortetramethoxypropane; 0.2 ml of 8.1% sodium 
dodecylsulphate; 1.5 ml of 20% acetic acid and 1.5 ml of aqueous 
solution of TBA up to 4 ml with distilled water) was heated to 
95°C for 30 min and then 1 ml of N-butanol and pyridine (15:1 
v/v) was added to plasma samples. The absorbance of the organic 
phase was measured at 532 nm (Mullane et al., 1985). The values 
were expressed as nanomoles of TBA-reactive substances (MDA 
equivalent) mg−1 of protein, determined with the Bradford 
method (Bradford, 1976) over an albumin standard curve.
Determination of myeloperoxidase (MPO) activity: 
myeloperoxidase, a reliable marker of leukocyte activation, 
was determined as described in the literature (Masini et al., 
2002) with some modifications: 100 ml of plasma was allowed 
to react with a solution 1.6 mM of tetramethylbenzidine and 
0.1 mM H2O2. The rate of change in absorbance was measured 
spectrophotometrically at 650 nm. MPO activity was defined as 
the quantity of enzyme degrading 1 μmol of peroxide per minute 
at 37°C and was expressed in mU per mg of protein, determined 
with the Bradford method (Bradford, 1976) over an albumin 
standard curve.
Determination of the cytokines: the levels of two pro‐
inflammatory cytokines, interleukin-6 (IL‐6) and tumor necrosis 
TABlE 1 | HQ-EVOO main constituents, analyzed by the Valoritalia Laboratories 
s.r.l., Tavarnelle Val di Pesa, Florence, Italy.
Main constituents Method mg/kg
Oleic acid Reg. CEE 2568/91 72.84
ß-carotene MI/C/002 rev 1 20/10/2004 232
Tocopherols (Vit. E) MI/C/002 rev 3 05/10/2009 197
Polyphenols MI/C/001 rev 4 05/10/2009 365
Tyrosol HPLC 2.65
3-hydrossi-Tyrosol HPLC 2.37
1-acetoxypinoresinol MI/C/003 rev 4 05/10/2009 48.50
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factor-α (TNF-α) and anti-inflammatory interleukin-10 (IL-
10) were measured on aliquots (50 μl) of plasma by using the 
Flow Cytomix assay (Bender Medsystems GmbH, Vienna, 
Austria), following the protocol provided by the manufacturer. 
Fluorescence was read with a cytofluorimeter (CyFlow® Space, 
Partec, Germany). Values are expressed as pg/μg of total proteins 
determined over an albumin standard curve (Bradford, 1976).
Monitoring of Gut Microbiota: DNA 
Extraction and Quantification
Total DNA (Agnelli et al., 2004) was extracted from fecal samples 
by following the QIAamp DNA Stool Mini Kit instructions 
(Qiagen) and quantified with a Qubit® 2.0 fluorometer 
(Invitrogen, USA). Molecular weight and fragment length 
of DNA were checked on 1.5% agarose gel; the yield was 
calculated as µg DNAg−1 feces. Quantitative PCR (qPCR) was 
conducted using the specific primers rpoB1, rpoB1o and rpoB2 
for the RNA-polymerase β subunit encoding gene, a valuable 
alternative as present in single copy per genome (Dahllöf et al., 
2000; Adékambi et al., 2008; Větrovský and Baldrian, 2013), that 
generate amplicons of 250-bp (Renouf et al., 2006), on 10 ng 
DNA for all the samples; negative control contained only ddH2O. 
Reactions were performed in a CFX Connect 96 apparatus 
(BioRad, Hercules, CA, USA) and the results were analyzed by 
the manufacturer’s software. Amplification was carried out in a 
25 µl final volume containing: 7.5 µM of each primer, 2.5 µg of 
BSA, 1X iTaq™ Universal SYBR® Green Supermix, sterile ddH2O 
to reach the appropriate volume. Amplification was performed in 
96-well micro titer plates (BioRad). The program cycle was: 95°C 
3 min followed by 35 cycles of 95°C 1 min, 45°C 1 min and 72°C 
1 min. After that, a melting curve program was run for which 
measurements were made at 0.5°C temperature increments 
every 10 s within a range of 60–100°C. A rpoB amplified and 
purified fragment (from a mix of LABs of a commercial probiotic 
formulation—Lactoflorene® Plus, Montefarmaco OTC, (Soldi 
et al., 2019)) was used as standard.
The standard curve was developed by plotting the logarithm of 
known concentrations (tenfold dilution series in triplicate from 
6.5 × 10-1 to 6.5 × 10−5 in 25 µl reaction) of the rpoB fragment 
against the threshold Cycle (Ct) values (Ceccherini et al., 2003). 
The qPCR standard curve had an R2 of 0.99–0.97 and an efficiency 
>85%. Three replicates were carried out for each sample for the 
two interval times: T0 and T1.
Statistical Analysis
Sample size calculation was performed to assess the minimum 
number of participants to be included in the study (website: http://
hedwig.mgh.harvard.edu/sample_size/size.html) (Schoenfeld, 
2001). It was calculated considering that 80% was the probability 
that the study revealed a difference of MPO levels between the 
two groups (cases and controls at T0) with a significance level of 
0.05, assuming that the set power was 0.8. The minimum sample 
size for this study was 18 subjects.
Data were reported as mean values of individual average 
measures of each subject. Delta (Δ) is the variation between T0 
and T1. Delta values were calculated by subtracting the final 
value at 3 months of MD from the corresponding initial value 
at baseline. Significance of differences among the groups was 
assessed by t-test or repeated measures two-way analysis of 
variance followed by Bonferroni’s post-hoc test using GraphPad 
Prism 4.03 statistical software, when appropriated, and 
QuickCalcs (GraphPad Software, Inc, La Jolla, CA).
RESUlTS
Subjects were divided in two arms according to their BMI: 
controls (6 males and 12 females non-obese subjects with a BMI 
at T0 21.6 ± 2.6 and at T1 21.7 ± 2.4 kg/m2, mean age 41.4 ± 
14.42), and cases (11 males and 7 females overweight/obese subjects 
with a BMI at T0 30.152 ± 4.8 and at T1 28.7 ±4.1 kg/m2, mean 
age 52.1 ± 13.04). The demographic and clinical characteristics 
of the studied population are described in Table 2.
Anthropometric and Hematochemical 
Parameters
Body weight and BMI were significantly different at the same time 
point between controls and cases (controls T0 vs cases T0 and 
controls T1 vs cases T1). Moreover, cases at T1 showed a significant 
decrease in BMI compared to T0. The Δ T1 − T0 confirmed that 
these differences were significant in cases (Table 3).
Total, HDL, LDL cholesterol and triglycerides did not show 
any statistical difference between cases and controls at T0 and 
T1. The Δ T1 − T0 of fasting glucose was significant in cases. 
Insulin and C-peptide were higher in cases both at T0 and T1 in 
comparison to controls (Table 3).
Oxidative Stress and Inflammatory 
Markers
Myeloperoxidase levels were significantly lower at time 
T1 than at time T0 in both controls and cases. The Δ T1 − 
T0 indicated that this difference was significant in cases 
(Figure 1). The amount of MDA, a marker of lipid peroxidation, 
was significantly lower at T1 both in controls and cases 
TABlE 2 | Demographics and clinical characteristics of the studied population.
Characteristics Controls n.18 Cases n.18
Age (years) 41.4 ± 14.42 (range 
24–71)
52.1± 13.04 (range 
20–61)*
Gender (male/female) M 6 + F 12 M 11 + F 7
Type 2 Diabetes (*) 0/18 1/18
Arterial Hypertension (**) 1/18 3/18
Smokers (more than 5 
cigarettes/day)
1/18 4/18
*Diagnosis of type 2 diabetes: fasting plasma glucose >126 mg/dl (7.0 mmol/l); 
according to American Diabetes Association Standards of Medical Care in 
Diabetes, 2017 (American Diabetes Association, 2017) and (**) diagnosis of 
arterial hypertension: >140/90 mmHg, according to the Task Force for the 
Management of Arterial Hypertension of the European Society of Hypertension 
and the European Society of Cardiology (Mancia et al., 2013). Values are mean ± 
SD for n = 18 subjects/group.
*p < 0.05, t-test was used for the analysis.
Frontiers in Pharmacology | www.frontiersin.org November 2019 | Volume 10 | Article 1366
HQ-EVOO and Inflammation in Obese and Normal AdultsLuisi et al.
5
(Figure 2A). The production of 8-OHdG, a reliable marker of 
DNA oxidative stress, measured at T1, both in controls and in 
cases, was significantly decreased in comparison to the values 
at T0, mostly in cases (Figure 2B).
The levels of TNF-α and IL-6 showed a decreasing trend from 
T0 to T1, both in controls and cases, although these differences 
were not significant (Figures 3A, B). Interestingly, in cases, the 
level of IL-10, an anti-inflammatory cytokine, was significantly 
higher at T1 than at T0; no statistical significant differences were 
found in controls (Figure 3C).
Adiponectin levels
At T0, the control group showed higher mean plasma adiponectin 
levels compared to those of cases. For both groups there was a 
statistically significant increase in adiponectin levels after MD 
rich in HQ-EVOO. T1 − T0 Δ resulted to be 0.6 ± 0.26 in controls 
while 1.6 ± 0.2 in cases (Figure 4).
Monitoring of the Gut Microbiota: Fecal 
Biomass DNA Extraction and lAB 
Quantification
In our study, the yield of dsDNA per gram of feces, extracted 
from all the samples, grouped as controls and cases at times T0 
and T1, was not significantly different, neither between cases nor 
between times (controls T0/T1, cases T0/T1, controls T0/cases 
T0, controls T1/cases T1, data not shown). We can be assumed 
that there was no modification measurable by Qubit.
Regarding the specific LAB’s rpoB sequences quantified by 
qPCR, significant differences were assessed between controls 
and cases as a function of time. The rpoB copy number per ng of 
template DNA was significantly increased in cases and controls at 
T1; while, at T0 the rpoB copies between controls and cases were 
not significantly different (Figure 5). In particular, the amount 
of rpoB copies in controls at T1 increased 11.4 times than those 
in the same samples at T0, while in cases at T1 rpoB amount 
TABlE 3 | Anthropometric and hematochemical parameters of the studied population.
Parameters Controls Cases ΔT1 − T0
T0 T1 T0 T1 Controls Cases
Weight (kg) 60.9 ± 3.1 61.2 ± 3.0 82.7 ± 3.4*** 79.2 ± 3.2*** 0.4 ± 0.4 −3.5 ± 1.2§
BMI (kg/m2) 21.6 ± 0.6 21.7 ± 0.6 30.2 ± 1.0*** 28.8 ± 0.9***,## 0.1 ± 0.1 −1.3 ± 0.4§
Total Cholesterol (mg/dl) 201.8 ± 9.9 201.2 ± 14.2 195.5 ± 7.6 197.6 ± 9.3 1.4 ± 5.9 2.0 ± 6.2
HDL Cholesterol (mg/dl) 51.0 ± 5.0 55.3 ± 5.2 58.5 ± 4.0 61.6 ± 3.8 4.3 ± 3.1 3.1 ± 2.2
LDL Cholesterol (mg/dl) 130.3 ± 8.1 125.8 ± 10.8 117.3 ± 7.4 117.8 ± 8.8 −4.5 ± 4.7 0.5 ± 5.0
Triglycerides (mg/dl) 102.5 ± 12.8 93.9 ± 7.7 98.9 ± 7.4 90.9 ± 6.0 −8.7 ± 17.4 −8.0 ± 8.2
Fasting glucose (mg/dl) 96.6 ± 3.9 92.0 ± 4.9 88.7 ± 1.9 91.0 ± 2.0 −4.7 ± 3.3 2.2 ± 1.4§
Insulin (µU/ml) 22.9 ± 2.3 21.7 ± 1.8 29.0 ± 1.4* 26.9 ± 1.4# −1.2 ± 0.9 −2.1 ± 0.5
C-peptide (ng/ml) 1.7 ± 0.1 1.6 ± 0.1 2.2 ± 0.1** 1.8 ± 0.1 −0.2 ± 0.03 −0.4 ± 0.1
*P < 0.05, **P < 0.01 and ***P < 0.001 vs control group at same time point (ex. Control T0 x Case T0 ).
#P < 0.05, ##P < 0.01 and ### P <0.001 vs T0 in the same group (ex. Control T0 x Control T1 ). 
Both Two-Way ANOVA and Bonferroni’s MCT.
§P < 0.05  vs controls. Unpaired t-test.
FIGURE 1 | Evaluation of myeloperoxidase (MPO) activity. Bar graph shows the plasma levels of the enzyme in controls and cases at T0 and T1. Delta (Δ) values 
are calculated by subtracting the final value at 3 months from the corresponding initial value at baseline. Values are mean ± S.E.M. for n = 18 subjects/group. **p < 
0.01, ***p < 0.001 vs T0 and vs controls. Two-way ANOVA followed by Bonferroni’s post-hoc test was used for the analysis of differences among the groups; t-test 
was used for the variation analysis (Δ T1 − T0).
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increased 55.6 times than those at T0. Moreover these results 
showed that the rpoB amount in cases at T1 were significantly 
higher than the ones in controls.
DISCUSSION
Obesity is a growing problem with epidemic proportions worldwide, 
has a great effect on diabetes and CVD risk and induces the 
production of several cytokines and inflammatory markers that 
contribute to CVD outcome in overweight and obese people (Van 
Gaal et al., 2006). A healthy MD was shown to be cardio-protective 
and has been linked to a number of health benefits. In this context, 
there is increasing evidence of health benefits of HQ-EVOO, the 
main fat in MD (Trichopoulou et al., 2014; Martín-Peláez et al., 
2017) and recent evidences suggest that extra virgin olive oil 
polyphenols health benefits, may be also related to the modulation 
of GM balance (Hervert-Hernández and Goñi, 2011).
The results of the present study suggest that HQ-EVOO is an 
important component of the anti-inflammatory action of MD, 
since MPO (a reliable marker of inflammation and endothelial 
dysfunction), 8-OHdG (a pro-mutagenic oxidative adduct in the 
DNA of all tissues and organs), TNFα and IL-6 (cytokines that impair 
insulin receptor signaling and activate inflammatory cascade) are 
significantly decreased in both cases and controls subjects. Plasma 
adiponectin, which induces IL-10 mRNA expression in human 
macrophages and IL-10 itself, increased at T1, suggesting a further 
protective role of HQ-EVOO rich in polyphenols. These compounds, 
such as oleuropein, have shown antioxidant, anti-inflammatory 
and anti-thrombotic properties, improving endothelial function 
(Oliveras-López et al., 2014). In particular, oleuropein improves 
postprandial glycaemia in healthy subjects via an oxidative stress‐
mediated mechanism (Carnevale et al., 2018). Moreover, our results 
suggest that gut LAB promptly responded increasing in number 
after the introduction of HQ-EVOO rich in polyphenols as the main 
fat component of the MD. Owing to its many roles in human health, 
there is great interest in deciphering the principles that govern an 
individual’s GM. Anyway, the inter-relationship between our dietary 
habits and the structure of our GM is still poorly understood. 
Preliminary data suggest that in mice dietary saturated fats, rather 
than unsaturated fats, indirectly modulate GM composition and 
may contribute to the development of metabolic syndrome (de 
Wit et al., 2012). In this regard, HQ-EVOO was rarely used as a 
monounsaturated fat for studies on its effects on human obesity, 
hepatic steatosis or GM composition.
FIGURE 2 | Evaluation of oxidative stress markers. (A) Bar graph shows 
the levels of malonyldialdehyde (MDA) in controls and cases at T0 and T1. 
(B) Bar graph shows the levels of 8-hydroxy-deoxyguanosine (8-OHdG) 
in controls and cases at T0 and T1. Delta (Δ) values are calculated by 
subtracting the final value at 3 months from the corresponding initial value at 
baseline. Values are mean ± S.E.M. for n = 18 subjects/group. *p < 0.05 vs 
control,**p < 0.01 vs T0; ***p < 0.001 vs T0. Two-way ANOVA followed by 
Bonferroni’s post-hoc test was used for the analysis of differences among the 
groups; t-test was used for the variation analysis (Δ T1 − T0).
FIGURE 3 | Determination of inflammation parameters. (A and B) Analysis of 
pro-inflammatory cytokines TNF-α and IL-6 content (respectively) in plasma 
samples of controls and cases at T0 and T1. (C) Bar graph shows the plasma 
levels of the anti-inflammatory cytokine IL-10 in controls and cases at T0 and 
T1. Values are mean ± S.E.M. for n = 18 subjects/group. ***p < 0.001 vs T0 
and vs control. ns = not significant. Two-way ANOVA followed by Bonferroni’s 
post-hoc test was used for the analysis of differences among the groups; 
t-test was used for the variation analysis (Δ T1 − T0).
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The phenolic fraction of HQ-EVOO, besides oleic acid, also acts 
as promoting factor of growth or survival for beneficial gut bacteria, 
mainly Lactobacillus strains, and inhibiting the proliferation of 
some pathogenic bacteria (Martín-Peláez et al., 2017).
The use of the rpoB gene in qPCR, the most quantitative 
and reliable tool to determine bacterial concentrations in 
environmental and clinical samples, allowed to refer directly 
to the number of LAB because this gene is present in single 
copy in the bacterial genome. In this work, the gut biomass as 
a whole, calculated by the dsDNA extracted from feces, did 
not significantly differ between cases and controls during the 
experiment. However, what caught our attention was, instead, 
the amount of rpoB sequences that is the significant increment 
of the number of LAB at the end of the monitoring diet period, 
in both cases and controls. At T0 the amount of LAB was not 
significantly different between controls and cases, but at T1, the 
presence of these bacterial population increased significantly in 
both groups and particularly in cases and in a relatively short 
period of time.
Although gender and age variations influence GM (Spychala 
et al., 2018; Santos-Marcos et al., 2019), in the present study 
these stratification analyses were not performed for the reduced 
number of the enrolled subjects; however, the higher effect of MD 
rich in HQ-EVOO, on anti-inflammatory cytokines and LAB, 
observed in overweight/obese than in normal weight subjects, 
indicates the validity of our hypothesis. Further investigation is 
needed to clarify the etiopathogenetic mechanism.
In conclusion, obesity, metabolic disease and inflammation 
are considered to be nutrition-related disorders and recent 
evidence indicates that GM plays a major role both in disease 
development and in wellness. Dietary polyphenols, such as 
those present in High Quality-Extra Virgin Olive Oil, are 
substrates that seem to contribute to the maintenance of GM, 
mainly Lactobacillus strains, and thus, exerting prebiotic 
actions. There are still few human trials that have been 
carried out to test the efficacy of MD as anti-obesity and anti-
inflammatory treatment by inducing a modification of Lactic 
Acid Bacteria. Our results, supporting the role of GM as an 
FIGURE 4 | Determination of plasma adiponectin as a marker of metabolic dysregulation. Bar graph shows the plasma levels of adiponectin in controls and cases 
T0 and T1. Delta (Δ) values are calculated by subtracting the final value at 3 months from the corresponding initial value at baseline. Values are mean ± S.E.M. for 
n = 18 subjects/group. *p < 0.05, **p < 0.01 vs T0 and vs control. Two-way ANOVA followed by Bonferroni’s post-hoc test was used for the analysis of differences 
among the groups; t-test was used for the variation analysis (Δ T1 − T0).
FIGURE 5 | LAB’s rpoB sequences quantification. Bar graph shows rpoB copy number/ng of DNA in controls and cases at T0 and T1. Values are mean ± S.E.M. 
for n = 18 subjects. *p < 0.05, **p < 0.01 vs T0 controls and ***p < 0.001 vs T0 cases. Two-way ANOVA followed by Bonferroni’s post-hoc test was used for the 
analysis of differences among the groups; t-test was used for the variation analysis (Δ T1 − T0).
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important element in the regulation of energy homeostasis, 
contribute to unveil the potential role of the MD focused on 
HQ-EVOO rich in polyphenols use, as a possible diet-related 
intervention, for decreasing inflammation and oxidative stress 
both in normal and overweight/obese subjects in prevention 
and rehabilitation.
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